The prevalence of chronic diseases has increased significantly over the past few decades.

 

The global targeted drug delivery device market size is projected to grow from $427 Million in 2026 to $2,153 Million by 2035, representing a CAGR of 19.7% during the forecast period.

 

During our research, we identified over 35 players that are engaged in development of targeted drug delivery devices. The market is characterized by the presence of established players and start-ups across the different regions. The maximum number (27%) of developers were established between 1951 and 2000, followed by developers established before 1900 (24%). Additionally, it is worth highlighting that there are few developers that have been established post-2010, indicating a growing demand for such devices and  increasing interest of stakeholders in this domain. Further, 51% of the device developers are headquartered in North America, followed by Europe (35%), Asia-Pacific and Middle East and North Africa (14%). Within North America, all the targeted drug delivery device developers are headquartered in the US. Examples include (arranged in alphabetical order, companies established Post-2000) Alcyone Therapeutics, BioCardia, Boston TransTec, OncoSec Medical and Seraxis.

 

The maximum number (47%) of the targeted drug delivery devices are currently being evaluated in preclinical stage of development, followed by devices in clinical stage (28%). The significant number of devices in preclinical and clinical stages can be attributed to the growing demand for such devices owing to their advantages, such as high target specificity, rapid therapeutic outcomes, and the potential to prevent the development of chronic diseases in future generations.

 

Over 30% of the devices are currently focused on delivering biologics directly to the brain, followed by heart (23%). Notably, the Extroducer, developed by Smartcella, is distinguished by its versatility, as it can be utilized to target multiple organs, including the heart, kidney, pancreas, and liver.

 

Further, majority (42%) of the devices have been designed for the targeted delivery of gene therapies and cell therapies. Examples of devices for targeted delivery of both gene therapies and cell therapies include (in alphabetical order of the developer name) Helix Biotherapeutic Delivery System (BioCardia), AVANCE Steerable Introducer (BioCardia), SmartFlow Neuro Ventricular Cannula (ClearPoint Neuro) and Orbit Subretinal Delivery System (Novartis).

 

Research objectives:

• The Targeted Drug Delivery Device Market report studies the worldwide market consumption rate in terms of value and volume.
• It identifies the various sub-segments of the market structure.
• It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.
• The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.
• Furthermore, the report underpins the strategic developments occurring in the global market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.

 

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.